Ubiquigent™ has the assays, expertise, and capabilities to drive forward every step in the drug discovery workflow, from DUB target identification and validation to the identification and characterisation of novel DUB targeting compounds in vitro, in cells and in tissues.
End-to-end platform for DUB drug discovery and development
Our specialised drug discovery platform and long-standing expertise is empowering scientists to develop DUB inhibitors, DUB-targeting PROTACs, and DUBTACs into exciting new medicines
Suite of comprehensive biochemical and cellular assays
DUBprofiler-Cell and DUBprofiler-Tissue
Flexible assays to determine target engagement and selectivity of DUB targeting compounds in cell lysates, cell cultures, or tissue samples
Mass spectrometry-based assay that rapidly profiles the entire proteome to identify and validate DUB targets and determine the mechanism of action for novel DUB targeting compounds
Critical counter-screening assay that separates false positives from genuine hits
Customised assays to investigate the mechanism of action of novel DUB targeting compounds
Unique ubiquitinomics assay for the comprehensive, unambiguous, and unbiased analysis of ubiquitination sites across the full proteome
Comprehensive set of assays to uncover the most appropriate DUB for a given target protein to drive the development of DUBTACs
Proprietary toolkit for mapping the active DUBome in diseased vs non-diseased human or animal tissues, cells, or subcellular compartments
The generation of physiologically ubiquitinated target proteins and in vitro deubiquitination using a panel of DUBs
Proximity profiling assay for cell-based proof-of-principle that induced DUB proximity leads to stabilisation of a target protein and the desired phenotype
Custom Assay Development
Bespoke assays to screen compounds against exciting new UPS targets as they continue to emerge across a wide range of human diseases
Chemistry expertise to design novel compounds
Proprietary DUB-Targeting Compounds
Novel compounds to provide new starting points for DUB-focused drug discovery programmes
Ubiquigent has a growing collection of novel DUB-targeting compounds that have been evaluated across our suite of comprehensive biochemical and cellular assays. These compounds represent a valuable resource for identifying new starting points for DUB-focused drug discovery programmes.
Highly experienced chemists in DUB drug discovery
Our chemists have worked on the design and development of DUB inhibitors for our internal pipeline and on behalf of our clients
Ubiquigent chemists are experienced at applying computational and medicinal skills to the design of DUB inhibitors, encompassing covalent and non-covalent compounds, and compounds with an allosteric mechanism of action.
Access to a range of relevant technologies through our growing network of collaborators and industry experts, including in structural biology
Ubiquigent has established a network of academic and industrial partners to augment our own experience, including structural biology, mass spectrometry and individual DUB target-based expertise. These existing partnerships alongside new collaborations as appropriate, can be leveraged to offer our clients an even more comprehensive DUB-focused partnership.